AI주식인사이트AI Stock Insight
C

영진약품

003520KOSPI

41.5 / 100

Reference Date: 2026-10-23

Financial Score13.0 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 5.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Youngjin Pharmaceutical, a core subsidiary of KT&G Group, has built trust through awards such as the Presidential Award and focuses on enhancing national health and the pharmaceutical industry. In 2025, it achieved sales of 2.543 trillion KRW and an operating profit of 34 billion KRW, strengthening its domestic market position and diversifying exports globally. It is driving growth through R&D investment and ESG management to solidify its position as a global pharmaceutical company.

Number of Employees

626people

Average Salary

69.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
2.00Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE
-0.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
79.18Industry Average 100.004.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲4.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲59.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -1.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 999Won52-week high 2,17052-week low 993
1-month return2.0Point

1m -5.75% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 1Neutral 0Negative 0
  • Positive[기재정정]단일판매ㆍ공급계약체결2026-10-08